USE OF ISCHEMIC PRECONDITIONING IN ONCOLOGY NURSING PROFESSIONALS

Simone Meneguetti Zatta; David Feder, Flávia S Gehrke,Beatriz C. A Alves, Ligia A Azzalis, Marcelo Rodrigues Bacci, Virginia Junqueira,Paloma Garrido,Fabiana Souza, Fernando L. A.Fonseca

Institution: Mestranda em Ciencias da Saúde pela FMABC

In Brazil, the mortality rates from breast cancer – the second most common type of cancer worldwide – are still high, since the disease is diagnosed at an advanced stage: only in 10% of cases the disease is diagnosed at an early stage, when cure rates reach 90 %. The most active agents for the treatment of breast cancers are the anthracyclines, but the clinical usefulness of these drugs is limited by a dose-dependent cumulative cardiac toxicity, which results in congestive heart failure. There is a growing interest in the identification of oncological patients who are at risk of developing cardiac abnormalities before symptoms appear. Serological markers and new cardiac imaging techniques have become the source of many studies aimed at screening patients for preclinical cardiotoxicity, and troponin I is a marker widely used in clinical practice for the evaluation of acute coronary syndromes. With all attempts to minimize the problems of post- chemotherapy cardiotoxicity, the remote ischemic preconditioning (RIPC) has been considered as a potent endogenous mechanism capable of inhibiting the inflammatory response, so this procedure may serve as a prophylaxis to prevent anthracycline- induced cardiotoxicity oncology. In this work, we suggest the use of RIPC by nursing professionals in the expectation that this is a facilitator for the development of strategy against chemotherapy side effects inherent element and contribute to improving the quality of life of patients after chemotherapy for breast cancer.